The Brief
What Insilico Medicine does
Insilico Medicine uses generative AI to design novel drug candidates, predict clinical trial outcomes, and identify new drug targets. The company has advanced multiple AI-designed compounds into clinical trials.
Builder’s Brief
Insilico Medicine is a healthcare tool on Falcoscan. AI drug discovery platform for novel therapeutics. Falcoscan rates Insilico Medicine with an Opportunity score of 88/100, a Saturation score of 8/100, and a Wrapper-risk score of 5/100. Market signal: hot. Insilico Medicine is founded in 2014, currently at Series_a stage. Pricing: Paid. Rating 4.7/5 across 100 tracked views.